Human plasma praoxonase (HuPON1): An anti-atherogenic enzyme with organophosphorsphate hydrolase activity;La paraoxonase du plasma humain (HuPON1): Une enzyme anti-athérogène à activité d'hydrolase d'organophosphorés

Annales Pharmaceutiques Francaises

Volumn 59, Issue 2, 2001, Pages 108-118

  Josse, D ^a   Masson, P ^a  

^a CENTRE DE RECHERCHES   (France)

Author keywords

Atherosclerosis; Catalytic scavenger; Organophosphates; Paraoxonase; Poisoning

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; HYDROLASE; LOW DENSITY LIPOPROTEIN; ORGANOPHOSPHATE; PHOSPHOLIPID; SCAVENGER;

ATHEROGENESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BINDING; ENZYME MODIFICATION; HUMAN; HYDROLYSIS; INTOXICATION; NONHUMAN; PROTEIN BINDING; PROTEIN STRUCTURE;

ARTERIOSCLEROSIS; ARYLDIALKYLPHOSPHATASE; ESTERASES; HUMANS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PHOSPHORIC ACID ESTERS; SUBSTRATE SPECIFICITY;

EID: 0035028835     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (74)

1. Organophosphorous compounds as chemical warfare agents
2. A review of organophosphate poisoning
3. Toxiques chimiques de guerre et terrorisme
4. Organophosphates chemistry, fate, and effects
5. Biotransformation enzyme polymorphism and pesticide susceptibility
6. Blood cholinesterases as human biomarkers of organophosphorous pesticide exposure
7. An enzyme in animal tissues capable of hydrolyzing the phosphorus-fluorine bond of alkyl fluorophosphates
8. Purification of human serum paraoxonase/arylesterase. Evidence for one esterase catalyzing both activities
9. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation
10. Apolipoprotein J is associated with paraoxonase in human plasma
11. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression
12. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
13. Carboxylesterase and A-esterase activities during maturation and aging: Relationship to the toxicity of chlorpyrifos and parathion in rats
14. The human serum paraoxonase - Polymorphism and specificity
15. Paraoxonase activity is reduced by a pro-atherosclerotic diet in rabbits
16. Short-term feeding of atherogenic diet to mice results in reduction of HDL and paraoxonase that may be mediated by an immune mechanism
17. Quantification of human serum paraoxonase by enzyme-linked immunoassay: Population differences in protein concentrations
18. Paraoxonase protects against chlorpyrifos toxicity in mice
19. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45. Identity of K-45 with paraoxonase
20. Lipoproteins and hydrolysis of organophosphorus compounds
21. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
22. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
23. Properties of the retained N-terminal hydrophobic leader sequence in human serum paraoxonase/arylesterase
24. Human serum Paraoxonase/Arylesterase's retained hydrophobic N-terminal leader sequence associates with HDLs by binding phospholipids: Apolipoprotein A-I stabilizes activity
25. Targeted disruption of the murine lecithin: Cholesterol acyltransferase gene is associated with reductions in plasma paraoxonase and platelet-activating factor acetylhydrolase activities but not in apolipoprotein J concentration
26. Comparison of purified human and rabbit serum paraoxonases
27. Calcium binding by human and rabbit serum paraoxonases, structural stability and enzymatic activity
28. Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase
29. X-ray crystallographic data of human paraoxonase
30. Characteristics of the genetically determined allozymic forms of human serum paraoxonase/arylesterase
31. The molecular basis of the human serum paraoxonase activity polymorphism
32. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: Glutamine or arginine at position 191, for the respective A or B allozymes
33. Role of genetic polymorphism of human plasma paraoxonase/arylesterase in hydrolysis of the insecticide metabolites chlorpyrifos oxon and paraoxon
34. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin
35. Human serum paraoxonase (PON1) isozymes Q and R hydrolyze lactones and cyclic carbonate esters
36. Identification of residues essential for human paraoxonase (PON1) arylesterase/organophosphatase activities
37. Paraoxonase (PON1) gene in mice: Sequencing, chromosomal localization and developmental expression
38. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family
39. Lactone-ring-cleaving enzyme: Genetic analysis, novel RNA editing, andevolutionary implications
40. Rabbit serum paraoxonase 3 (PON3) is an HDL-associated lactonase and protects LDL against oxidation
41. Selective plasma hydrolysis of glucocorticoid gamma-lactones and cyclic carbonates by the enzyme paraoxonase: An ideal plasma inactivation mechanism
42. On the physiological role(s) of the paraoxonases
43. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: Step 1
44. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein. Steps 2 and 3
45. LDL oxidation by arterial wall macrophages depends on the oxidative status in the lipoprotein and in the cells: Role of prooxidants vs. Antioxidants
46. HDL, its enzymes and its potential to influence lipid peroxidation
47. Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio
48. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein
49. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
50. Low serum paraoxonase: A risk factor for atherosclerotic disease?
51. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities
52. High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis
53. Oxidized low density lipoprotein: Atherogenic and proinflammatory characteristics during macrophage foam cell formation. An inhibitory role for nutritional antioxidants and serum paraoxonase
54. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis
55. Lack of protection against oxidative modification of LDL by avian HDL
56. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities
57. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
58. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: Selective action of human paraoxonase allozymes Q and R
59. Does paraoxonase play a role in susceptibility to cardiovascular disease?
60. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients
61. The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease
62. Evidence for association between paraoxonase gene polymorphisms and atherosclerotic diseases
63. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins
64. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
65. Oxidized phospholipids induce changes in hepatic paraoxonase and apo J but not monocyte chemoattractant protein-1 via interleukin-6
66. Tailoring new enzyme functions by rational redesign
67. Protein technologies and commercial enzymes
68. The PON1 gene and detoxication
69. Effect of overexpression of human apo A-I in C57BL/6 and C57BL/6 apo E-deficient mice on 2 lipoprotein associated enzymes, platelet-activating factor acetylhydrolase and paraoxonase
70. Régulation de l'expression du gène PON1 codant la paraoxonase humaine
71. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis
72. Cysteine substitutions in Apolipoprotein A-1 primary structure modulate paraoxonase activity
73. Hydrolysis of platelet-activiting factor by human serum paraoxonase